The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigation of predictive biomarkers in patients treated with atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802).
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical
 
Shogo Kumagai
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Saori Mishima
No Relationships to Disclose
 
Takumi Habu
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroki Hara
Honoraria - Asahi Kasei; Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; dainippon sumitomo; MSD; Ono Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Keisho Chin
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shun-ichiro Kageyama
No Relationships to Disclose
 
Hidehiro Hojo
No Relationships to Disclose
 
Masaki Nakamura
Honoraria - AstraZeneca; Varian Medical Systems
Consulting or Advisory Role - MSD
 
Tachibana Hidenobu
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Makoto Fukui
No Relationships to Disclose
 
Nozomu Fuse
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Stock and Other Ownership Interests - Cellian-Biclo; Sustainable Cell Therapeutics
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD K.K; Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; Eisai; Fujifilm; Hitachi; Janssen Research & Development; Kyowa Kirin; MSD K.K.; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; SRL Diagnostics; Sumitomo Dainippon Pharma; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; BMS; Merck; MSD
Research Funding - Astellas Amgen BioPharama (Inst); BMS (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)